Transcript Slide 1

Technology & Methods Seminar
 “Blast and Other Methods of Probabilistic
Sequence Comparison”
Arcady Mushegian
Bioinformatics
Thursday, May 25, 1:00p.m.
Classroom
(1st floor, Administration Building)
Schedule with abstracts and previous presentation slides can be found on:
K:\Weekly Seminar Schedule\Thursday -- Technology & Methods
Information regarding previous seminars can be found at:
http://research.stowers-institute.org/wiw/external/Seminars/index.htm
..
Laurence FLORENS
[email protected]
Proteomics
Rooms 351-357
bm
X
ie
L
R
on i
g_
L
Tr i
a
W in o
or
r
km
an
D
u
G
er
K to n
ru
m
J a la
sp uf
er
se
n
B
a
au yr
m
a
C nn
of
fm
C
o n an
aw
ay
A
Number of samples
Over 2000 Samples Analyzed since Oct 2003
300
250
200
2003
150
2004
2005
100
2006
50
0
High-Throughput Proteomics: MudPIT
Cells
Tissues
Embryos
Proteins
Lysis
Purification
Peptide Mixture
Digestion
Tandem Mass Spectrometry
2D Chromatography
Protein List
Data Analysis
Database Matching
MS/MS Spectrum
Complex Protein Mixtures
Cells
Tissues
Embryos
Proteins
Lysis
Purification
Peptide Mixture
Digestion
Tandem Mass Spectrometry
2D Chromatography
Protein List
Data Analysis
Database Matching
MS/MS Spectrum
Complex Protein Mixtures
Types of samples we deal with:
 Whole cell lysates
 Membrane/Organelle preps
 Co-IPed proteins
 Affinity purified proteins
 Any biochemically-sound protein mixture and appropriate negative controls
Quantities:
 low µg to 500µg
What we need to know about your samples:
 Details of prep:
 Organism
 Amino acid sequence(s)
 Buffer
 Concentration, Silver-stained gel, Western Blot
 Protein content or PTMs
Drop off:








-80°C Freezer (Hallway Room 351)




Complex Protein Mixtures - Troubleshooting
Sample form:
 Small starting volume (<50ul) can be digested directly
 Dried protein pellet after TCA-precipitation (PREFERRED)
Problems with “Sticky Stuff”:
 Glycerol
 High Detergent (e.g. 2% SDS)
 DNA/RNA
Solutions:
 Keep as low as possible or dialyze out
 Methanol/Chloroform extraction
 Benzonase
w/o Benzonase
w/ Benzonase
RT: 0.00 - 20.05
RT: 0.00 - 116.97
NL:
3.86E9 100
Base Peak
MS
95
ScMcd1Myc_Meta_
90
Ti_401
3.45
100
95
3.96
2.85
90
RT: 0.00 - 20.02
100
95
90
13.19
100
74.50
83.00
10.99
89.42
84.82
13.84
95
95.75
90.38
97.63
103.33
107.94
112.42
14.10
90
10.40
85
4.02
85
RT: 0.00 - 117.08
NL:
1.11E9
Base Peak
MS
ScMcd1Myc_Meta_
Ti_101
NL:
4.29E9
Base Peak
MS
ScMcd1Myc_Meta_
Ti_102
80
80
75
80
75
70
39.52
65
4.29
4.35
71.42
70
70
70.43
65
65
69.51
68.86
60
Relative Abundance
Relative Abundance
60
55
0.79
50
45
1.00 1.80
2.01
40
1.09
18.30
35
45
30
40
25
2.57
2.82 2.96
20
9.76
15
9.13
6.94 7.23
6.23 6.30
7.82
3.79
5
10
8.41
8.73
9.01
0
1
25
2
3
4
5
6
7
8
9
11.63
11
12.62
12
14.61 15.16 15.96 16.51
13
14
15
16
17
89.94
99.47
20.33
18.08
0
1
2
3
4
5
6
7
8
9
14.65
19
20
0
10
22.65
86.33
11.11
108.52
97.22
79.25
77.28
94.19
85
116.69 NL:
4.27E9
Base Peak
MS
ScMcd1Myc_Meta_
Ti_103
30
40
50
60
Time (min)
70
80
90
100
12
13
14
15
16
17
18
19
20
102.65
95
101.42
90
111.66
85
107.77
NL:
4.28E9
Base Peak
MS
ScMcd1Myc_Meta_
114.87 Ti_104
85
80
71.43
66.68
55
50
82.96
45
60.85
15
15.76
45.16
18.93
23.97
29.18
70
80
90
100
110
44.50
10
20
30
40
50
60
Time (min)
70
80
90
100
50.85
5
23.82
26.07
58.53
67.93
10
20
30
40
50
60
Time (min)
75.03 78.81 82.01
70
80
88.52 91.16
90
NL:
4.28E9
114.70
Base Peak
112.65
MS
ScMcd1Myc_Meta_
Ti_106
96.94 101.06 104.86
105.10
94.62
100
110
0
NL:
1.63E9
Base Peak
MS
ScMcd1Myc_Meta_
Ti_405
54.39
95
90
15.50
75
58.32
10
20
30
40
50
67.03
60
Time (min)
106.32 112.18 115.49
75.92 78.37 82.45 89.21 93.72
70
80
90
100
110
NL:
1.44E9
Base Peak
MS
ScMcd1Myc_Meta_
Ti_406
60.58
100
95
62.41
90
85
85
80
80
75
75
75
91.20
70
70
70
48.73
50.28
32.85
0
RT: 0.00 - 97.06
100
111.38
105.99
20.98 22.53
6.32 12.02 12.77
115.10
102.45 106.32
92.73
80
80
23.01
110
RT: 0.00 - 117.03
85
15
10
8.17 12.51 14.05 14.85
16.40
RT: 0.00 - 117.05
MS
ScMcd1- 90
Myc_Meta_
Ti_105
85
5.57 11.08
90
62.56
46.78
34.71
100
NL:
3.87E9
95
Base Peak
95
61.33
20
31.56
5
0
0
0
RT: 0.00 - 117.03
0.31
100
5.27
3.82
45.69
25
10
53.72
54.12
51.93
0
60
Time (min)
30
35.58 40.04
28.54
50
35
35.97
15
67.59
53.56
52.57
10
5
40
60.85
40.47
40
62.38
59.29
51.09
0
30
45
20
73.59
70.17 72.24
45.62
20
20
60.68
55
74.89
25
60.70
10
90
50
43.18
25
52.33
0
46.42
30
30
20
NL:
3.23E9
Base Peak
MS
ScMcd1Myc_Meta_
Ti_404
54.25
95
60
55
50
35
76.39 81.26
35
63.28
61.75
52.75
52.58
110
65
45.12
40
40
35
44.36
100
39.72
100
84.46
45
40
43.35
37.69 38.38
34.21
90
70
Relative Abundance
Relative Abundance
86.35
Relative Abundance
55
15.24
15.90 20.88
80
75
60
94.99
60
5
70
95.58 98.48
90.04
60
15
60
Time (min)
61.77
65
10
50
80
75
70
25
40
112.46
87.31
13.58
65
30
104.38 109.83
30
85
39.77
75
70
65.36
20
12.85
80
73.93
65
45
10
RT: 0.00 - 116.96
NL:
1.88E9
Base Peak
MS
ScMcd1Myc_Meta_
Ti_403
54.86
90
76.50
14.11
70
50
0
110
RT: 0.00 - 117.02
3.62 5.41 9.00
100
12.61
80
75
99.95
0
10
11
Time (min)
95
83.56
80.03
7.24
94.08
88.39
35.71
32.68
20
100
84.10
8.25 10.44
103.61
83.04
74.56
68.26
24.55 26.60
13.89
2.67 4.38
18.70 19.32
16.14 16.91 17.44
81.00
65.38
16.33
12.31 13.06 13.70
10.61
8.64 9.25 9.63
RT: 0.00 - 117.05
4.15
3.38
95
90
73.68
16.02
14.47
5
5.07
5.24 5.49
6.24 7.28
0
18
RT: 0.00 - 117.00
100
58.11
36.88
15.77
10
4.83
34.05
4.57
5
10
Time (min)
20
15
4.56
0
40.27 40.82
63.14
52.16
4.49
1.38
1.31
1.03
5
5.26
19.21 19.93
10.53
0
37.67
30
15.16
1.64
1.51
1.44
10
15.38
5.75
3.50
10
93.19
56.40
35
15
52.26
46.08
44.62
40
20
63.32
62.27
54.66 60.63
9.98
53.57
18.26
3.02
3.43
15
50
45
4.42
1.71
25
64.82
47.99
30
2.50
25
55
2.30
2.22
65.40
35
2.22
30
20
50
45
50
2.15
35
55
47.81
40
68.60
65.99
55
60
Relative Abundance
Relative Abundance
60
Relative Abundance
62.84
75
2.71
70
72.09
65
58.27
70
65
65
65
Relative Abundance
50
12.79
60
55
90.43
15.70
50
45
45
40
90.27
40
35
65
60
Relative Abundance
12.50
Relative Abundance
55
61.15
60.86
60
12.25
60
Relative Abundance
89.81
85
80
75
NL:
3.07E9
Base Peak
MS
ScMcd1Myc_Meta_
Ti_402
62.49
85
4.22
55
50
45
55
92.36
50
45
92.03
40
40
35
35
89.40
35
30
30
13.43
30
25
90.91
30
90.20
25
20
97.55
104.01
15
14.46
5
19.57 24.59
29.85 34.98 39.99
10
20
30
40
67.58
60
Time (min)
23.03 26.65 30.43
0
70
80
88.97
87.87
80.14 81.91 84.46
78.65
73.70
13.51
20
15
12.37
12.11
15
10
0
50
25
20
5
0
0
86.73
86.38
10
60.60
45.12
61.70
25
11.37
115.26
14.07
14.79
65.73
88.26
70.75
52.70
53.54
9.65
6.55 7.66
110.85
89.51
76.03 78.79
10
10.19
20
105.69
94.70
15
90
100
110
10
20
30
40.92 44.19 49.10
40
50
54.53
62.06
60
Time (min)
71.29 75.96 77.30
70
33.81 40.52
83.49
80
90
100
 13 IDed Proteins
110
5
6.05
11.79
12.62
42.20
49.10
10
77.40
39.53
13.30
20.62 21.88
32.02
20
30
47.76
44.82
58.59
67.15 69.31
80.00
0
0
10
40
50
60
Time (min)
70
6.64
4.17
5
80
85.85 87.94
90
116.79
99.71 107.29 111.12
100
110
11.20
10.66
7.55
66.66 73.24
16.14
18.98
0
0
5
10
15
20
26.92 29.17
25
30
36.15 40.29
35
40
47.11
45
53.91
50
Time (min)
57.81
56.76
55
60
65
70
75
80
 67 IDed Proteins
85
90
95
Generating Peptides
Cells
Tissues
Embryos
Proteins
Lysis
Purification
Peptide Mixture
Digestion
Tandem Mass Spectrometry
2D Chromatography
Protein List
Data Analysis
Database Matching
MS/MS Spectrum
Generating Peptides
Proteomic Surveying: Endoproteinase Lys-C + Trypsin
MKLSEVFEQE IDPVMQSLGY CCGRKLEFSP QTLCCYGKQL CTIPRDATYY SYQNRYHFCE
KCFNEIQGES VSLGDDPSQP QTTINKEQFS KRKNDTLDPE LFVECTECGR KMHQICVLHH
EIIWPAGFVC DGCLKKSART RKENKFSAKR LPSTRLGTFL DSMCRLELKL NSS
Generating Peptides
Proteomic Surveying: Endoproteinase Lys-C + Trypsin
MKLSEVFEQE IDPVMQSLGY CCGRKLEFSP QTLCCYGKQL CTIPRDATYY SYQNRYHFCE
KCFNEIQGES VSLGDDPSQP QTTINKEQFS KRKNDTLDPE LFVECTECGR KMHQICVLHH
EIIWPAGFVC DGCLKKSART RKENKFSAKR LPSTRLGTFL DSMCRLELKL NSS
PTMs: High Sequence Coverage
MSQAIAEKQP SQEVKMEAKM EVDQPEPADT QPEDISESKV EDCKMESTET EERSTELKTE
IKEEEDQPST SATQSSPAPG QSKKKIFKPE ELRQALMPTL EALYRQDPES LPFRQPVDPQ
LLGIPDYFDI VKSPMDLSTI KRKLDTGQYQ EPWQYVDDIW LMFNNAWLYN RKTSRVYKYC
Generating Peptides
Proteomic Surveying: Endoproteinase Lys-C + Trypsin
MKLSEVFEQE IDPVMQSLGY CCGRKLEFSP QTLCCYGKQL CTIPRDATYY SYQNRYHFCE
KCFNEIQGES VSLGDDPSQP QTTINKEQFS KRKNDTLDPE LFVECTECGR KMHQICVLHH
EIIWPAGFVC DGCLKKSART RKENKFSAKR LPSTRLGTFL DSMCRLELKL NSS
PTMs: High Sequence Coverage
MSQAIAEKQP SQEVKMEAKM EVDQPEPADT QPEDISESKV EDCKMESTET EERSTELKTE
IKEEEDQPST SATQSSPAPG QSKKKIFKPE ELRQALMPTL EALYRQDPES LPFRQPVDPQ
LLGIPDYFDI VKSPMDLSTI KRKLDTGQYQ EPWQYVDDIW LMFNNAWLYN RKTSRVYKYC
Post-Translational Modifications: Triple/Multiple Digest
• Sample is split into x aliquots
• Digest using x different proteases
• Analyze samples individually
• Interpret spectra using SEQUEST
MacCoss et al. (2002) Proc Natl Acad Sci U S A. 99:7900-7905
Trypsin
Subtilisin
Elastase
MudPIT
MudPIT
MudPIT
Generating Peptides: DmSNS
SP
Extracellular
86.6% 5 Ti + 2 Es + 1 PK
(1479 AA, 162kDa)
Maggie Chen, Kiran Kocherlakota, Jeff McDermott
…
Cytodomain
Maggie Chen, Kiran Kocherlakota, Jeff McDermott
Generating Peptides - Troubleshooting
 No tryptic peptides are obtained from particular protein
 Overdigestion with non-specific proteases
 No positively charged amino acids in peptides
Multidimensional Chromatography
Cells
Tissues
Embryos
Proteins
Lysis
Purification
Peptide Mixture
Digestion
Tandem Mass Spectrometry
2D Chromatography
Protein List
Data Analysis
Database Matching
MS/MS Spectrum
Multidimensional Chromatography
Small digest volumes (<200µl):
3-phase 100µm Fused Silica
Large digest volumes (>200µl):
split-3-phase 250µm Fused Silica
100µm FS
100µm FS
RP - C18
250µm FS
RP - C18
waste
SCX
Filtered Union
with 2µm Frit
250µm FS
250µm FS
RP - C18
SCX
RP - C18
Peptides
Peptides
Multidimensional Chromatography
• Cycle 1 – Reverse Phase Gradient
• Cycle 2_Step 1 – Salt Pulse
• Cycle 2_Step 2 – Reverse Phase Gradient
H2O
MeCN NH4OAc
• Cycle 3_Step 1 – Increase Salt Pulse
• Cycle 3_Step 2 – Reverse Phase Gradient
HPLC
60
Buffer (%)
40
20
2.4kV
0
0
20
40
60
Time (min)
80
100
Number of Cycles depends on Sample Complexity
Tandem Mass Spectrometry
Cells
Tissues
Embryos
Proteins
Lysis
Purification
Peptide Mixture
Digestion
Tandem Mass Spectrometry
2D Chromatography
Protein List
Data Analysis
Database Matching
MS/MS Spectrum
Tandem Mass Spectrometry
Deca-XP vs LTQ
(3D vs Linear Ion Trap)
Hardware improvements for LTQ:
 Trapping efficiency (no rf field in ion injection axis),
 Ion capacity (linear configuration of mass analyzer -> larger volume),
 ~2x Detection efficiency (radial ejection of ions + 2 detectors)
 ~3x Ion ejection rate (while maintaining same resolution)
 Should significantly improve the number of detected peptides/proteins
Blackler et al. (2006) Anal. Chem.78:1337-13344
160
140
120
100
80
Spectral Count
220
60
20
XP
LTQ
AK
00
04
11
/I
TRnter
s
CRAP2 ex
SP20
R 70
SBgr1
TR M R7
e
T AP d8
TRRA 100
APP3
26
T S3
AR TRAur 0
C1RAP92
05 P85
/P 0
TR NuC2
A t2
MP
LC ED37
M 6
TRSu R1
APrf5
HSAR 24a
C0
TRPC292
TR
FL
96
A
AP
J1
01 T CDP95
24
93RA K
0re
/M P28
la
ed 5
te
d/ CTR 25
KI D F
AAK P
111
M 025
E
M D8
ED
7
--
Number of Proteins
Tandem Mass Spectrometry
Deca-XP vs LTQ
240
~10µg FLAG-tagged Mediator Prep
Total
Mediator
300
180
 ~2.5x more Protein IDs
 More Proteins that matter: not necessarily
 More spectra per protein (Quantitation, PTMs)
XP
LTQ
200
250
200
150
100
40
50
0
0
Tandem Mass Spectrometry
XP
Varying amounts of SpRunt1 (535AA, 59kDa)
Constant HsMediator (~20µg Total)
800
LTQ
Varying amounts of Pfs25 (185AA, 20kDa)
Constant HsMediator (~10µg Total)
XP
LTQ
Spectral Count
700
600
500
400
300
200
100
0
1E-4
1E-3
0.01
0.1
Spiked Protein (% of Total Protein Quantity, w/w)
 Both machines: Detection limit is ~0.05% of Total Protein Quantity (w/w)
 LTQ: more peptides/spectra detected for same quantities, i.e. greater confidence
Tandem Mass Spectrometry
The increase in number of spectra obtained from the LTQ results in:
 much larger files (x10)
 significantly increase in computational overhead (Storage and Search Time)
Blackler et al. (2006) Anal. Chem.78:1337-13344
Computational Overhead
Dan Thomasset
Computational Overhead
Dan Thomasset
Instrumentation Priorities
XP
 On-going Protein Identification Projects
LTQ
1. Quantitation (isotopic labeling)
2. PTMs
3. Low Abundance Proteins
4. New Protein Identification Projects
Matching MS/MS Spectra to Peptides
Cells
Tissues
Embryos
Proteins
Lysis
Purification
Peptide Mixture
Digestion
Tandem Mass Spectrometry
2D Chromatography
Protein List
Data Analysis
Database Matching
MS/MS Spectrum
Matching MS/MS Spectra to Peptides
Search engine: SEQUEST®
Protein Sequence Databases:
 Need to be as comprehensive as possible (whole genomes)
 Need to include “custom” sequences
 Updates
Shuffled Sequences:
 Used to estimate False Discovery Rates (FDR)
FDR 
2 x( Shuffled_ SpectralCount)
TotalSpectralCount
Data Analysis
Cells
Tissues
Embryos
Proteins
Lysis
Purification
Peptide Mixture
Digestion
Tandem Mass Spectrometry
2D Chromatography
Protein List
Data Analysis
Database Matching
MS/MS Spectrum
Filtering & Assembling Data: DTASelect
 Through P: drive
 http://bioinfo/proteomics/
SQTs
PARSE
DTASelect
ASSEMBLE
FILTER
High-stringency Filtering Criteria to limit FDR:
 Cross-correlation score (XCorr)
 DeltaCN
 Peptide Length
 Peptide Ends
Tabb et al. (2002) J Proteome Res 1: 21-26
DTASelect.html (DTASelect-filter.txt)
Comparing Protein Lists: CONTRAST
n Protein Lists
CONTRAST
COMPARE
MERGE
Contrast.html (Contrast.txt)
Text files
MSAccess
Tabb et al. (2002) J Proteome Res 1: 21-26
Comparing Protein Lists: contrast-report
n Protein Lists
contrast-report
Mike Coleman
COMPARE
report.xls
Dan He
Comparing Protein Lists: contrast-report
n Protein Lists
contrast-report
Mike Coleman
COMPARE
report.xls
Dan He
Relative Abundance: NSAF
Quantitative Information from MudPIT dataset?
 Sequence Coverage: high for small proteins / low for large proteins
 Spectral Count: large proteins contribute more peptides/spectra
Normalized Spectral Abundance Factor
( NSAF) k 
( SpectralCount / Length) k
N
 (SpectralCount / Length)
i 1
i
 Values between 0 and 1
 Best approximation of protein levels in a sample
 Allows comparisons across multiple runs and across different instruments
Relative Abundance: NSAF
Erika Geisbrecht
Mingan Shi
PTM Analysis
Modification
Delta Mass
Residues
Symbol
Methylation
14
KST
#
Hydroxylation
16
KD
@
Oxidation
16
M
@
Dimethylation
28
RK
~
Acetylation
42
KST
^
Phosphorylation
80
STY
*
Ubiquitination
114
K
%
Glycosylation:
 N-linked: PNGFase, which leaves modified N (Dmass= +1 Da)
 O-linked: beta-eliminate O-glycosylations with NH4OH, which
leaves modified S and T (Dmass= -1 Da)
PTM Analysis Flowchart
Mike Coleman
ptm-report
Mike Coleman
contrast-ptm
Time-line